NBSE NASDAQ
Pittsburgh, PA 15219
US
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Symetryx Corp | S-Sale | 50,000 | $1.19 | 2023-09-18 |
| Symetryx Corp | S-Sale | 103,337 | $1.26 | 2023-09-15 |
| Symetryx Corp | S-Sale | 129,108 | $1.44 | 2023-09-14 |
| Symetryx Corp | S-Sale | 3,376 | $1.44 | 2023-09-11 |
| Symetryx Corp | S-Sale | 128,847 | $1.53 | 2023-09-08 |